Digestion and gut comfort is the main area connected here, and any felt benefit should be read together with the human evidence base.
The 75.5 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the B tier remains conservative.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
Potential benefit studied in Digestion and gut health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Cognition and focus. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Immune and respiratory health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This range includes studies in specific patient groups. It is not a general dose or recommendation.
Standalone side-effect signals and combination cautions are listed separately.
Paper IDs and full lists are private. Only study types and summaries are shown.
ITF consumption selectively modulates Bifidobacterium spp.
It is shown in multiple murine tumour models that inulin—a widely consumed dietary fibre—formulated as a ‘colon-retentive’ orally administered gel can effectively modulate the gut microbiome in situ, induce systemic memory-T-cell responses and amplify the anti
Inulin’s unique physico-chemical properties bestow it with many useful pharmaceutical applications, and this review explains how inulin’s unique physico-chemical properties bestow it with many useful pharmaceutical applications.
Evidence from studies included in the current review suggest that ITF have a prebiotic effect on the intestinal microbiota, promoting the abundances of Bifidobacterium, Lactobacillus, and Faecalibacterium prausnitzii.
Investigating the mechanistic role of the gut microbiota in ameliorating NASH via dietary fibre in mice found soluble fibre inulin was found to be more effective than insoluble fibre cellulose to suppress NASH progression in mice, as shown by reduced hepatic s
Prebiotic administration compared with placebo significantly improved two frailty criteria, e.g., exhaustion and handgrip strength, and the use of novel therapeutic approaches influencing the gut microbiota–muscle–brain axis could be considered for treatment o